News Sentiment

REGN sentiment intelligence

Regeneron Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 664.52 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

+1.6% over one week, +8.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap?

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 1.6% Price digesting
Trend fit Trend inactive 8.6% over four weeks
Fair value -14.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 26
Negative 15

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 18
simplywall.st 6
Simply Wall Street 4
GuruFocus 4
Ad Hoc News 3
Moomoo 3
MarketWatch 2
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 15
Analyst action 10
Deals and strategy 3
Regulatory and legal 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Simply Wall Street Direct company coverage

Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap?

Regeneron Pharmaceuticals (REGN) recently experienced a clinical trial setback, causing its stock price to decline by almost 13% over 90 days, despite a 20.39% 1-year return. Analysts still view the stock as undervalued, with a fair value target of $833.31 against a current price

Tone
Positive 64/100
Event
Analyst action
Published
15 Jul 2026 12:54
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease

Vertex Pharmaceuticals (VRTX) is acquiring Crinetics Pharmaceuticals in a US$10 billion all-cash transaction, marking its entry into adrenal disease therapeutics. This acquisition includes atumelnant, a late-stage clinical drug candidate for congenital adrenal hyperplasia. The de

Tone
Positive 66/100
Event
Deals and strategy
Published
15 Jul 2026 12:51
Source
Simply Wall Street
Market source Direct company coverage

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Alnylam Pharmaceuticals presented significant advancements in its neuroscience portfolio at AAIC 2026, focusing on RNAi therapeutics for neurological diseases. Key announcements include the initiation of a global Phase 2 study for mivelsiran in Down Syndrome-Associated Alzheimer'

Tone
Positive 64/100
Event
Market update
Published
15 Jul 2026 07:45
Source
Market source
MarketWatch Direct company coverage

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day

Regeneron Pharmaceuticals Inc. (REGN) saw its stock slide by 1.05% to $656.12, marking its third consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index (SPX) rose 0.38% and the Dow Jones Industrial Average (DJIA) ros

Tone
Negative 40/100
Event
Market update
Published
14 Jul 2026 23:08
Source
MarketWatch
GuruFocus Direct company coverage

Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilumab

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that its medication dupilumab received FDA orphan drug designation, a status granted to drugs for rare diseases that offers benefits like tax credits and market exclusivity. This designation is a significant milestone, enhan

Tone
Positive 64/100
Event
Market update
Published
14 Jul 2026 21:56
Source
GuruFocus
Ad Hoc News Direct company coverage

Regeneron stock holds firm as the focus shifts to the pipeline

Regeneron Pharmaceuticals, Inc. (REGN) is a Nasdaq-listed biotech company focusing on a diversified drug portfolio and a late-stage pipeline. The company's business model generates revenue from marketed medicines and collaboration agreements, with its research platform centered o

Tone
Positive 67/100
Event
Earnings
Published
14 Jul 2026 06:14
Source
Ad Hoc News
Simply Wall Street Direct company coverage

Is Vertex Pharmaceuticals (VRTX) A Bargain On Its Expanded CASGEVY Approval?

Vertex Pharmaceuticals (VRTX) recently received expanded US approval for its gene therapy CASGEVY for children with sickle cell disease or beta thalassemia, influencing its stock performance. Despite a recent dip, the stock maintains long-term momentum and trades significantly be

Tone
Neutral 50/100
Event
Regulatory and legal
Published
14 Jul 2026 00:56
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Did Disappointing Trial Data Amid Strong Dupixent and Eylea Sales Just Shift Regeneron’s (REGN) Investment Narrative?

Regeneron Pharmaceuticals (REGN) recently experienced a setback with disappointing clinical trial results, raising concerns about its near-term pipeline productivity despite strong sales of Dupixent and Eylea and active share repurchases. This contrast has led to a shift in inves

Tone
Negative 39/100
Event
Earnings
Published
13 Jul 2026 21:38
Source
Simply Wall Street
Trefis Direct company coverage

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Incyte presents a clearer path for biotech investors seeking growth compared to Regeneron. While Regeneron manages complexities with its massive blockbusters and relies on pipeline faith, Incyte has raised its full-year guidance and is showing accelerating growth outside its main

Tone
Negative 37/100
Event
Guidance
Published
13 Jul 2026 17:37
Source
Trefis
Investing.com Direct company coverage

Cantor Fitzgerald reiterates Overweight on Regeneron stock

Cantor Fitzgerald reiterated an Overweight rating on Regeneron Pharmaceuticals Inc. with a price target of $750.00. The firm discussed the potential of Regeneron's pozelimab/cemdisiran treatment for retinal conditions, noting cautious optimism from a key opinion leader about its

Tone
Positive 63/100
Event
Analyst action
Published
13 Jul 2026 12:38
Source
Investing.com
Investing.com Canada Direct company coverage

Cantor Fitzgerald reiterates Overweight on Regeneron stock By Investing.com

Cantor Fitzgerald has reaffirmed its Overweight rating on Regeneron Pharmaceuticals Inc. with a price target of $750, despite previously lowering it from $785 due to concerns about Eylea HD/SD and Dupixent performance. The firm's positive outlook is based on Regeneron's pozelimab

Tone
Positive 65/100
Event
Analyst action
Published
13 Jul 2026 12:35
Source
Investing.com Canada
Market source Direct company coverage

Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2

Longleaf Partners Fund's Q2 2026 investor letter noted that Regeneron Pharmaceuticals (REGN) was a detractor due to disappointing trial results for one of its pipeline drugs. While Dupixent's performance exceeded expectations and Eylea stabilized, the company's "one out of three"

Tone
Negative 39/100
Event
Earnings
Published
13 Jul 2026 10:33
Source
Market source
Law360 Direct company coverage

Regeneron Cites Medtronic Ruling In Amgen Bundling Case

Regeneron has invoked a recent Medtronic ruling in a California federal court to bolster its $407 million victory against Amgen. This action was taken in a Delaware federal court, where Regeneron is seeking to preserve its win in a case concerning the bundling of cholesterol drug

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 01:09
Source
Law360
GuruFocus Direct company coverage

REGN Maintained by Piper Sandler -- Price Target Lowered to $854

Piper Sandler has maintained an Overweight rating on Regeneron Pharmaceuticals (REGN) but slightly lowered its price target from $855 to $854. Despite this minor adjustment, the company is considered 26.5% undervalued according to GuruFocus's GF Value™ and holds a strong GF Score

Tone
Positive 65/100
Event
Analyst action
Published
09 Jul 2026 16:22
Source
GuruFocus
Moomoo Direct company coverage

Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855

Piper Sandler has slightly decreased its price target for Regeneron Pharmaceuticals (REGN) from $855 to $854. The firm maintained an Overweight rating on the stock. This adjustment reflects a minor change in Piper Sandler's valuation outlook for the pharmaceutical company.

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jul 2026 15:38
Source
Moomoo
GuruFocus Direct company coverage

REGN Maintained by Morgan Stanley -- Price Target Lowered to $73

Morgan Stanley has maintained an Equal-Weight rating on Regeneron Pharmaceuticals (REGN) but lowered its price target from $788 to $730, citing a cautious outlook. Despite this, GuruFocus indicates REGN is undervalued by 26.5% with a strong GF Score™ of 78/100, driven by excellen

Tone
Negative 39/100
Event
Analyst action
Published
08 Jul 2026 22:45
Source
GuruFocus
MarketWatch Direct company coverage

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Regeneron Pharmaceuticals Inc. (REGN) stock declined by 1.97% to $662.88 on Wednesday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also fell. The company's stock closed 19.27% below its 52-week high.

Tone
Negative 28/100
Event
Market update
Published
08 Jul 2026 20:43
Source
MarketWatch
Bloomberg Law News Direct company coverage

Regeneron Narrows Amgen Challenges in Case Over Eylea Biosimilar

Regeneron Pharmaceuticals Inc. successfully moved to dismiss Amgen Inc.'s fraud-based defenses and certain antitrust claims concerning proposed Eylea biosimilars. However, a federal judge allowed Amgen to continue arguing that Regeneron delayed too long in pursuing a specific pat

Tone
Positive 61/100
Event
Regulatory and legal
Published
08 Jul 2026 15:59
Source
Bloomberg Law News